Galatea Bio has secured $25 million in funding to expand its biobank initiative and advance AI-driven genomic research with a focus on underrepresented populations. The Miami-based biotechnology company plans to sequence 10 million participants worldwide, prioritizing individuals of non-European ancestry to address a significant gap in current genomic datasets.
The funding round includes investments from F-Prime, Helios Digital Ventures, Digitalis Ventures, CEI Ventures, AME Cloud, Alexandria, Founders Collective, Stanford President's Fund, and HBM Genomics. This capital will support the company's expansion from its current Biobank of the Americas to the more comprehensive Galatea Global Biobank.
"Galatea Bio envisions a future where healthcare is accessible to all and tailored to each individual's genetic makeup and predicted future disease trajectory," said Carlos D. Bustamante, Ph.D., CEO and President of Galatea Bio. "By analyzing a broad spectrum of genetic, longitudinal health records, and real-world evidence data from multi-ancestry populations, Galatea is generating new insights into the biological processes that underlie health and disease."
Addressing Critical Gaps in Genomic Research
Founded in 2021, Galatea Bio is tackling one of the most significant challenges in genomics research: the lack of diverse population data. Currently, most genomic datasets are heavily skewed toward patients of European ancestry, limiting the applicability of genetic insights for global populations.
The company operates a College of American Pathologists (CAP)-accredited biobank and clinical genetic testing laboratory. With the new funding, Galatea Bio will expand its clinico-genomics platform to integrate multi-modal data and AI-driven applications for genetic risk analysis, biomarker discovery, and clinical trials optimization.
Wale Ayeni, Managing Partner at Helios Digital Ventures, highlighted the importance of this work: "Africa holds the richest tapestry of human genetic variation on Earth yet remains mostly absent in global genomics research. This gap not only limits our understanding of human biology but obscures pathways to medical breakthroughs that could benefit humanity globally."
Innovative Tools for Precision Medicine
The company recently launched the StrataRisk Polygenic Risk Score API, designed to improve genetic risk predictions for individuals of non-European ancestry. Traditional Polygenic Risk Score (PRS) models—which estimate an individual's inherited risk of developing certain diseases—have been primarily developed using European genetic data, often yielding less accurate results for other populations.
By utilizing AI-enhanced ancestry inference, Galatea Bio is developing proprietary polygenic risk scores and improving disease modeling for drug target discovery across multiple therapeutic areas, including:
- Cardiometabolic diseases
- Neurodegenerative disorders
- Immune diseases
- Cancer
- Other complex diseases
"Galatea Bio is already a well-established leader in genomics, with a strong foundation of collaborations driving innovation in research and personalized medicine," said Muzammil Mansuri, Venture Partner at F-Prime. "Their approach unlocks the full potential of genetic data at scale, transforming how we understand and apply genomics to human health."
Strategic Partnerships and Technical Capabilities
Galatea Bio has established strategic partnerships with industry leaders including Illumina and Oxford Nanopore to advance its Global Biobank initiative. The company has also secured collaborations with health systems such as Baptist Health - South Florida, which serve patient populations enriched for non-European ancestries.
Operating from a CAP-accredited, high-complexity NGS laboratory in Miami, Galatea Bio provides full-service sequencing, molecular diagnostics, and AI-enhanced genomic analysis. The company's proprietary platforms—Galaxy-bio™ and Gnomix AI™—enhance ancestry-aware polygenic risk scoring, pharmacogenomics, and disease prediction models.
Leadership Expansion
As part of its growth strategy, Galatea Bio has announced key leadership appointments:
- Jeff Gulcher, MD, PhD, joins as Chief Medical Officer
- Francisco M. De La Vega, D.Sc., as Chief Technology Officer
- Muzammil Mansuri, PhD (formerly of Sanofi, Gilead, and Flagship Pioneering) and Wale Ayeni have joined the Board of Directors
The company's intellectual property portfolio includes licenses from Stanford University and the Chan-Zuckerberg Initiative, positioning Galatea Bio at the forefront of genetic research and analysis while continuously innovating new methods to interrogate and interpret genomic data.
With its expanded funding and focus on diverse genetic data, Galatea Bio aims to transform precision medicine by ensuring that genomic advances benefit all populations, regardless of ancestry.
